Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis

Fridman, Moshe; Hodgkins, Paul; Kahle, Jennifer; Erder, M. Haim

doi:10.1016/j.eurpsy.2015.01.001

Cited by 16 publications

(13 citation statements)

References 37 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 56 , 57 Therefore, the conclusions from the current study may also apply to a European population. 58 While this study may inform practice in Europe, further research is warranted to confirm the consistency of the findings in a European population.…”

Section: Discussionmentioning

confidence: 63%

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine

Joseph¹,

Cloutier²,

Guérin³

et al. 2016

PPA

View full text Add to dashboard Cite

PurposeTo compare treatment adherence, discontinuation, add-on, and daily average consumption (DACON) among adults with attention-deficit/hyperactivity disorder receiving second-line lisdexamfetamine dimesylate (LDX) or atomoxetine (ATX), following methylphenidate.Patients and methodsA retrospective cohort study using US commercial claims databases (Q2/2009–Q3/2013).ResultsAt month 12, the LDX cohort (N=2,718) had a higher adherence level (proportion of days covered: 0.48 versus 0.30, P<0.001) and was less likely to discontinue (Kaplan–Meier estimate: 63% versus 85%, P<0.001) than the ATX cohort (N=674). There were no statistical differences in treatment add-on rates between cohorts (Kaplan–Meier estimate: 26% versus 25%, P=0.297). The LDX cohort had a lower DACON (1.10 versus 1.31, P<0.001) and was less likely to have a DACON >1 (adjusted odds ratio: 0.20, 95% confidence interval: 0.15–0.25, P<0.001) than the ATX cohort.ConclusionAdults with attention-deficit/hyperactivity disorder treated with LDX following methylphenidate had a higher treatment adherence and lower discontinuation and DACON relative to those treated with ATX following methylphenidate.

show abstract

Section: Discussionmentioning

confidence: 63%

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine

Joseph¹,

Cloutier²,

Guérin³

et al. 2016

PPA

View full text Add to dashboard Cite

show abstract

“…The same drugs are used across the lifespan in clinical practice, but only methylphenidate, lisdexamfetamine, and atomoxetine are officially approved for treatment of ADHD in childhood and adulthood in most European countries (Ramos-Quiroga et al., 2013). Unsurprisingly, there have been many more clinical trials evaluating the efficacy and safety of these drugs in children than in adults (Faraone and Buitelaar, 2010, Fridman et al., 2015). Nevertheless, randomised, placebo-controlled clinical trials and meta-analyses convincingly show the effectiveness and safety of both stimulant and non-stimulant drugs for ADHD also in adults (Epstein et al., 2014, Fridman et al., 2015) (Table 1).…”

Section: Treatment and Response To Treatment Over Time – Pharmacologimentioning

confidence: 99%

Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan

Franke

Michelini

Asherson

et al. 2018

European Neuropsychopharmacology

444

361

View full text Add to dashboard Cite

Attention-deficit/hyperactivity disorder (ADHD) is highly heritable and the most common neurodevelopmental disorder in childhood. In recent decades, it has been appreciated that in a substantial number of cases the disorder does not remit in puberty, but persists into adulthood. Both in childhood and adulthood, ADHD is characterised by substantial comorbidity including substance use, depression, anxiety, and accidents. However, course and symptoms of the disorder and the comorbidities may fluctuate and change over time, and even age of onset in childhood has recently been questioned. Available evidence to date is poor and largely inconsistent with regard to the predictors of persistence versus remittance. Likewise, the development of comorbid disorders cannot be foreseen early on, hampering preventive measures. These facts call for a lifespan perspective on ADHD from childhood to old age. In this selective review, we summarise current knowledge of the long-term course of ADHD, with an emphasis on clinical symptom and cognitive trajectories, treatment effects over the lifespan, and the development of comorbidities. Also, we summarise current knowledge and important unresolved issues on biological factors underlying different ADHD trajectories. We conclude that a severe lack of knowledge on lifespan aspects in ADHD still exists for nearly every aspect reviewed. We encourage large-scale research efforts to overcome those knowledge gaps through appropriately granular longitudinal studies.

show abstract

“…Since increased blood pressure and heart rate in general are considered risk factors for cardiovascular morbidity and mortality during adult life, paediatric patients using ADHD medication should be monitored closely and regularly for heart rate and blood pressure. 32 Rare side effects include QTc interval prolongation, epilepsy, and increased risk of suicide related events 33 (table 2⇓).…”

Section: How Safe Is Stimulant Use In Adhd?mentioning

confidence: 99%

Stimulant medication to treat attention-deficit/hyperactivity disorder

Santosh

2017

BMJ

View full text Add to dashboard Cite

Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis

Abstract: This model predicts that LDX may have a large treatment effect size in European adults with ADHD.

Cited by 16 publications

References 37 publications

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine

Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan

Stimulant medication to treat attention-deficit/hyperactivity disorder

Contact Info

Product

Resources

About